Company Background

Semprus BioSciences' mission is to establish a new standard-of-care by significantly reducing serious health complications associated with medical devices, improving patient outcomes and contributing to healthcare cost efficiencies.

Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. Our innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Our current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification.

Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform - which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of our Semprus Sustain™ Technology, a permanent non-leaching biomaterial modification to the device surface, our technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. We have assembled a world class product development team - scientists, industry executives and clinical experts - who specialize in reducing such complications at the confluence of the human body and implantable devices.

In December 2010, Semprus BioSciences completed an $18 million Series B financing round co-led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic. Prior to this, Semprus completed a Series A financing round co-led by a venture capital firm focused on building next-generation life science companies, 5AM Ventures, and Pangaea Ventures, a venture capital firm that invests in advanced materials, energy, biomedical, and environmental technology companies, in December 2008. This funding came on the heels of our $2.5 million seed capital raised in 2007.

Additionally, we have worldwide licenses secured from MIT and the University of Washington, and hold numerous proprietary intellectual property filings. Our laboratory and office complex is located in Kendall Square, Cambridge's innovative biomedical center, and employs 27 full-time professionals.